Maze Therapeutics is a biotechnology company which offers small molecule precision medicines to patients with common diseases. Their approach integrates human genetics, functional genomics, and therapeutic discovery to identify genetic modifiers that may influence disease progression or outcomes. Maze Therapeutics applies its proprietary Compass™ platform striving to incorporate variant functionalization into each stage of drug development. This company was founded by Mark Daly Ph.D, Stephen Elledge Ph.D, Aaron Gitler Ph.D, Sekar Kathiresan MD, and Jonathan Weissman Ph.D in 2018 and is headquartered in South San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/03/2024 | Series D-1 | $41.7MM | $xx.xx | $551.86MM | Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital | |
Price per Share
$xx.xx
Shares Outstanding
37,795,823
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
|
||||||
12/03/2024 | Series D | $73.3MM | $xx.xx | $551.86MM | Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital | |
Price per Share
$xx.xx
Shares Outstanding
53,145,012
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
|
||||||
01/10/2022 | Series C | $120.62MM | $xx.xx | $742.72MM | Andreessen Horowitz, Casdin Capital, City Hill Ventures, Direhaus Capital Management, Foresite Capital, General Catalyst, Matrix Capital Management, Moore Strategic Ventures, Ns Investments, Terra Magnum Capital Partners, Woodline Partners | |
Price per Share
$xx.xx
Shares Outstanding
40,866,704
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Casdin Capital, City Hill Ventures, Direhaus Capital Management, Foresite Capital, General Catalyst, Matrix Capital Management, Moore Strategic Ventures, Ns Investments, Terra Magnum Capital Partners, Woodline Partners
|
||||||
10/25/2019 | Series B | $158.3MM | $xx.xx | $596.01MM | City Hill Ventures | |
Price per Share
$xx.xx
Shares Outstanding
57,563,188
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
City Hill Ventures
|
||||||
02/28/2019 | Series A | $104.99MM | $xx.xx | $149.98MM | Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Foresite Capital, Gv, Third Rock Ventures | |
Price per Share
$xx.xx
Shares Outstanding
104,985,132
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Foresite Capital, Gv, Third Rock Ventures
|